Prestige Consumer Healthcare Inc. to Post FY2024 Earnings of $4.33 Per Share, Zacks Research Forecasts (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) - Investment analysts at Zacks Research boosted their FY2024 EPS estimates for shares of Prestige Consumer Healthcare in a research report issued to clients and investors on Monday, April 22nd. Zacks Research analyst R. Department now anticipates that the company will post earnings of $4.33 per share for the year, up from their prior forecast of $4.32. The consensus estimate for Prestige Consumer Healthcare's current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare's Q4 2024 earnings at $1.14 EPS, Q4 2026 earnings at $1.20 EPS and FY2026 earnings at $4.75 EPS.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 8th. The company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.04 by $0.02. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The firm had revenue of $282.74 million for the quarter, compared to the consensus estimate of $280.25 million. During the same quarter in the previous year, the firm earned $1.04 EPS. The company's quarterly revenue was up 2.6% compared to the same quarter last year.

Several other research firms also recently weighed in on PBH. TheStreet raised shares of Prestige Consumer Healthcare from a "c+" rating to a "b-" rating in a research report on Monday, February 12th. StockNews.com raised shares of Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a research report on Saturday, February 10th. One equities research analyst has rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to MarketBeat, Prestige Consumer Healthcare currently has an average rating of "Moderate Buy" and a consensus target price of $110.00.

Prestige Consumer Healthcare Stock Performance

NYSE:PBH traded up $1.42 during trading hours on Tuesday, hitting $71.23. 166,699 shares of the company were exchanged, compared to its average volume of 240,256. The stock has a market capitalization of $3.54 billion, a price-to-earnings ratio of -43.53, a PEG ratio of 1.89 and a beta of 0.52. Prestige Consumer Healthcare has a 52-week low of $55.96 and a 52-week high of $75.31. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.09 and a quick ratio of 1.92. The company's 50 day moving average price is $70.73 and its 200-day moving average price is $63.94.

Insider Activity

In related news, SVP Mary Beth Fritz sold 5,336 shares of the company's stock in a transaction dated Thursday, February 8th. The shares were sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the sale, the senior vice president now owns 15,934 shares of the company's stock, valued at $1,099,446. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.60% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Trexquant Investment LP boosted its stake in Prestige Consumer Healthcare by 109.1% during the third quarter. Trexquant Investment LP now owns 8,340 shares of the company's stock worth $477,000 after buying an additional 4,351 shares during the period. Qube Research & Technologies Ltd lifted its position in shares of Prestige Consumer Healthcare by 91.4% during the third quarter. Qube Research & Technologies Ltd now owns 72,092 shares of the company's stock worth $4,123,000 after purchasing an additional 34,430 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth about $1,632,000. Connors Investor Services Inc. acquired a new stake in shares of Prestige Consumer Healthcare during the third quarter worth about $1,569,000. Finally, Hsbc Holdings PLC lifted its position in shares of Prestige Consumer Healthcare by 17.1% during the third quarter. Hsbc Holdings PLC now owns 22,075 shares of the company's stock worth $1,263,000 after purchasing an additional 3,226 shares in the last quarter. Hedge funds and other institutional investors own 99.95% of the company's stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.